Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10792280 | 0.84 | SMN1; SMN2 (0.49) | MPOSMN1; SMN2ADORA2AADORA1LMNA | |
| SCHEMBL10791105 | 0.80 | LMNA (0.46) | SMN1; SMN2GPR84LMNA | |
| SCHEMBL16016409 | 0.77 | MPO (0.40) | MPOP2RX7SMN1; SMN2AKR1B1ADORA2A | |
| SCHEMBL10792269 | 0.75 | GPR84 (0.38) | P2RX7SMN1; SMN2GPR84MAPK1 | |
| SCHEMBL10792018 | 0.74 | SMN1; SMN2 (0.41) | P2RX7SMN1; SMN2GPR84 | |
| SCHEMBL16016416 | 0.73 | LMNA (0.47) | MPOSMN1; SMN2LMNAGRM4 | |
| SCHEMBL16020971 | 0.73 | MPO (0.41) | MPOP2RX7SMN1; SMN2AKR1B1CD38 | |
| SCHEMBL10885165 | 0.73 | FABP4 (0.37) | ADORA2AADORA1 | |
| SCHEMBL16016418 | 0.73 | MPO (0.41) | MPOP2RX7SMN1; SMN2AKR1B1ADORA2A | |
| SCHEMBL10795374 | 0.72 | TAAR1 (0.40) | P2RX7SMN1; SMN2ADORA2AADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774928-B1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2774928-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | MPO 4689/4885P2RX7 1820/4885SMN1; SMN2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.